ClinicalTrials.gg
RecruitingNCT05820243Updated Nov 28, 2023

Determinants of Changes in Arterial Load Following Exercise

An interventional study of Moderate Intensity Aerobic Exercise in Post-Exercise Hypotension, sponsored by University of Delaware. Recruiting at 1 site in United States. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-11-28.

Sponsored by University of Delaware · Not applicable, Interventional, and Basic science

From the registry’s dates

  • Primary completion was expected by Apr 2024, 2 years 7 months ago, but the record still lists the study as recruiting.
  • Started May 2023; still recruiting 3 years 5 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
25
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Study summary

The goal of this study is to learn about how blood vessel dilation after exercise effects pulse wave reflection and influences the function of the heart in healthy young adults. The main question it aims to answer is: Are post-exercise decreases in reflected pulse waves due to a decrease in the stiffness of large arteries in the leg or an increase in leg blood flow? Participants will exercise on a stationary bicycle at a moderate intensity for 1 hour during two laboratory visits. Participants will take oral antihistamines to block post-exercise dilation at one visit, and they will take placebo pills at the other visit. At both visits, leg blood flow, pulse wave velocity, and heart function will be measured before exercise and for 120-minutes after exercise.

Read the detailed description

During exercise, blood vessels increase in size to supply muscles with more blood. After exercise, the muscles that had been used release chemicals called histamines that cause the blood vessels to stay dilated even when the muscles no longer need more blood. It takes around 2 hours for the blood vessels to return to normal. This causes blood pressure to be lower than it usually is at rest. This phenomenon delays the return of pressure waves in arteries that are reflected back to the heart resulting in the heart having to work less hard to pump out blood for about 2 hours after exercise. However, it is unknown why the reflected pressure waves return to the heart later. The aim of this study is to determine if this delay is due to the speed of the reflected waves being slowed by large arteries or dilation of small arteries resulting in the reflections originating further from the heart. By giving antihistamines prior to exercise, post-exercise blood vessel dilation of the small arteries will be largely reduced, thus allowing for the determination of which factor causes the reflected waves to return later. Additionally, it is hypothesized that the reduction in work that the heart must perform results in improved contraction and relaxation of the heart. Thus, an additional aim is to determine how post-exercise blood vessel dilation influence heart function.

To accomplish these aims, blood flow leaving the left ventricle and femoral blood flow will be measured via Doppler ultrasound. Applanation tonometry will be used to record pulse waves at the carotid, radial, femoral, and dorsalis pedis arteries. These pulse waves will be used to estimate central blood pressure and to determine pulse wave velocity of different arterial segments. Measurements will be made at baseline and for 120 minutes after a bout of moderate intensity aerobic exercise.

02

Conditions studied

  • Post-Exercise Hypotension

Keywords

  • arterial stiffness
  • wave reflections
  • pulsatile load
03

In context

Post-Exercise Hypotension

22 studies on the registry are indexed under Post-Exercise Hypotension; 2 are open to participants now.

This study's planned enrollment of 25 is above the median of 21 across 22 interventional studies indexed under Post-Exercise Hypotension.

Browse Post-Exercise Hypotension studies →

Lead sponsor

University of Delaware is the lead sponsor of 128 studies on the registry; 22 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • healthy men and women
  • sedentary or recreationally active

Exclusion criteria

Exclusion Criteria:

  • history of cardiovascular events or procedures
  • stage 2 hypertension (BP: ≥140 systolic or ≥90 diastolic)
  • metabolic syndrome
  • renal disease
  • chronic respiratory disease
  • currently prescribed any cardiovascular medication
  • current use of erythromycin and/ ketoconazole
  • current pregnancy or breastfeeding -hormone replacement therapy-
  • tobacco use
  • musculoskeletal injury/disorder that would inhibit cycling exercise
  • (BMI) \<18.5 or >35kg/m\^2
  • reduced kidney function (estimated \< 90ml/min/1.73 m\^2)
  • daily use of fexofenadine and/or famotidine
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
25 participants (estimated)

Study arms

  • Experimental
    Antihistamine

    The oral antihistamine condition will consist of fexofenadine (540mg) and famotidine (40mg). Commercially available pills (3 x 180mg fexofenadine and 2 x 20mg famotidine) will be placed within opaque capsules and administered to the participants upon arrival to the laboratory.

    Other: Moderate Intensity Aerobic Exercise

  • Placebo comparator
    Placebo

    The placebo condition will consist of dextrose in an identical number of opaque capsules as the antihistamine treatment. Total dextrose will be \<5g. The capsules will be administered to the participants upon arrival to the laboratory.

    Other: Moderate Intensity Aerobic Exercise

Interventions

  • OtherModerate Intensity Aerobic Exercise

    Participants will complete 1 hour of exercise on a cycle ergometer at the power output that elicits 60% of their peak rate of oxygen consumption (V02peak).

06

What researchers measure

Primary outcomes

  1. Change in lower limb arterial stiffness

    Arterial stiffness of the leg will be assessed via measurement of femoral-pedis pulse wave velocity.

    Time frame: 120 minutes post-exercise

  2. Change in leg vascular conductance

    Vascular conductance, an index of peripheral vasodilation, will be determined by measuring femoral blood flow via ultrasound and dividing by mean arterial pressure.

    Time frame: 120 minutes post-exercise

  3. Change in left ventricular pulsatile load

    Doppler echocardiography and arterial tonometry will be used to establish left ventricular pressure-flow relations. Wave separation analysis will subsequently be performed to determine the magnitude and timing of reflected pulse waves.

    Time frame: 120 post-exercise

Secondary outcomes

  1. Change in left ventricular diastolic function

    Echocardiographic measures of left ventricular diastolic function will be recorded, including mitral annulus tissue velocity and mitral in-flow velocity

    Time frame: 120 minutes post-exercise

07

Study locations

1 of 1 sites recruiting
  • Department of Kinesiology and Applied Physiology, University of Delaware
    Newark, Delaware 19713, United States
    Recruiting
    • David Edwards, PhD · Contactdge@udel.edu
    • Jordan Patik, PhD · Contactjpatik@udel.edu
    • David Edwards, PhD · Principal investigator
    • Jordan Patik, PhD · Principal investigator
    • Zoe Lincoln, BS · Sub investigator
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2023 (actual). Primary completion is estimated for Apr 2024, 11 months after the start.

Of 14 interventional studies with no phase under Post-Exercise Hypotension, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 15. This study's planned 11 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 16, 2023
First posted
Apr 19, 2023
StartActual
May 12, 2023
Primary completionEst.
Apr 2024
CompletionEst.
Sep 2024
Last update
Nov 28, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 28, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05820243
Responsible party
David Edwards (Professor, University of Delaware) — Principal investigator
First posted
Apr 19, 2023
Start date
May 12, 2023
Primary completion
Apr 2024 (estimated)
Completion
Sep 2024 (estimated)
Last update
Nov 28, 2023

Study contacts

David Edwards, PhD
Contact
dge@udel.edu
302-831-3363
Jordan Patik, PhD
Contact
jpatik@udel.edu
5128206387

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion